1. Home
  2. AKBA vs CMCO Comparison

AKBA vs CMCO Comparison

Compare AKBA & CMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.40

Market Cap

375.0M

Sector

Health Care

ML Signal

HOLD

Logo Columbus McKinnon Corporation

CMCO

Columbus McKinnon Corporation

HOLD

Current Price

$15.58

Market Cap

429.4M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKBA
CMCO
Founded
2007
1875
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Construction/Ag Equipment/Trucks
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
375.0M
429.4M
IPO Year
2014
2002

Fundamental Metrics

Financial Performance
Metric
AKBA
CMCO
Price
$1.40
$15.58
Analyst Decision
Strong Buy
Buy
Analyst Count
4
2
Target Price
$5.25
$21.00
AVG Volume (30 Days)
2.2M
359.2K
Earning Date
05-07-2026
05-27-2026
Dividend Yield
N/A
1.79%
EPS Growth
93.94
N/A
EPS
N/A
0.30
Revenue
N/A
$936,240,000.00
Revenue This Year
N/A
$19.73
Revenue Next Year
N/A
$82.91
P/E Ratio
N/A
$51.97
Revenue Growth
N/A
3.27
52 Week Low
$1.14
$13.31
52 Week High
$4.08
$24.40

Technical Indicators

Market Signals
Indicator
AKBA
CMCO
Relative Strength Index (RSI) 49.33 50.11
Support Level $1.30 $13.83
Resistance Level $1.56 $17.82
Average True Range (ATR) 0.08 0.66
MACD -0.00 0.23
Stochastic Oscillator 33.90 70.49

Price Performance

Historical Comparison
AKBA
CMCO

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

About CMCO Columbus McKinnon Corporation

Columbus McKinnon Corp is a designer, manufacturer, and marketer of intelligent motion solutions, including motion control products, technologies, automated systems, and services that efficiently and ergonomically move, lift, position, and secure materials. Its key products include hoists, crane components, precision conveyors, actuators, rigging tools, light rail workstations, and digital power and motion control systems. The company's targeted market verticals include general industries, process industries, industrial automation, and e-commerce/supply chain/warehousing among others. Geographically, the company generates a majority of its revenue from the United States and the rest from Germany, Canada, Asia Pacific, Latin America, Europe, the Middle East, and Africa.

Share on Social Networks: